Larotrectinib is approved for use in solid tumors that exhibit an NTRK gene fusion, regardless of the tumor's location in the body. This includes a variety of cancers, such as sarcoma, thyroid cancer, and lung cancer. Its approval for use is based on the presence of the genetic mutation rather than the cancer type, making it a tumor-agnostic treatment.